AtlasEdge Further Expands Coverage Across Europe with Acquisition of Twelve Data Centres from Colt Data Centre Services (DCS)
2.11.2021 12:00:00 EET | Business Wire | Press release
AtlasEdge, a pan-European edge data centre provider, has today announced the successful acquisition of twelve data centres. The deal is with Colt DCS, a world-class provider of Hyperscale data centres across Europe & APAC.
The successful acquisition from Colt strengthens AtlasEdge’s unique portfolio of distributed data centres that are positioned to support localised or low latency applications. AtlasEdge now operates more than 100 data centres across eleven countries in Europe, supporting more than 700 customers and providing connectivity to more than 50 different on-net carriers.
AtlasEdge provides a pan-European data centre portfolio that allows customers to design and configure their technology and network infrastructure to meet the growing requirements for lower latency, higher performance and localised solutions. With demand gravitating towards the edge of networks, AtlasEdge’s distributed and highly connected footprint provides a unique solution that is aligned with the next wave of growth in digital infrastructure.
This acquisition further expands AtlasEdge’s coverage and accelerates time to market in several new geographies, as well as establishing a collaboration between AtlasEdge and Colt Data Centre Services, with Colt Technology Services becoming an anchor tenant across multiple facilities. This network-neutral colocation strategy enables AtlasEdge’s customers to optimise their network routes, minimise their bandwidth costs and take advantage of the wide community of cloud, content, technology and enterprise companies present in the facilities.
The portfolio includes data centers in key tier one and tier two markets across Europe, including Amsterdam, Barcelona, Berlin, Brussels, Copenhagen, Hamburg, London, Madrid, Milan, Paris and Zurich.
“We are delighted to welcome these sites into our expanding portfolio,” commented Josh Joshi, Executive Chairman, AtlasEdge. “We are tapping into an exciting and emerging market where real time data traffic is growing and compute is gravitating to the edge of the network. As this demand builds, AtlasEdge is uniquely positioned to deliver seamless, localised and ultra-low latency digital infrastructure to our customers — from cloud providers to streaming services and enterprises. Our approach is open, carrier neutral and collaborative, and we look forward to working alongside Colt.”
Niclas Sanfridsson, CEO, Colt DCS, added, “Demand for data storage and cloud capabilities has never been higher, and so is the need for businesses to scale and find capacity. By restructuring and focusing on our hyperscale facilities, we can meet our customers’ needs on demand with true scalability and efficiency, while meeting their sustainability targets. We are committed to ensuring a sustainable business model for the future and this latest deal will improve the returns on investment across our portfolio, which can then be reinvested into the business.”
ABOUT AtlasEdge
AtlasEdge is a European edge data centre business with a mission to create Europe’s leading edge platform, delivering seamless, localised and ultra-low latency digital infrastructure to customers. Formed through a joint investment by Liberty Global, one of the world’s leading converged video, broadband and communications companies and DigitalBridge, a leading global investment firm dedicated to digital infrastructure, AtlasEdge already has an expanding portfolio of more than 100 data centres across the continent, providing proximity to the core network that is critical for the technology of tomorrow.
For more information, please visit www.atlasedge.com
ABOUT Colt DCS
Colt Data Centre Services provide true service and operational excellence in the sustainable design, build, delivery and operational management of hyperscale data centres across Europe and the APAC. We provide data centre solutions to hyperscale and large enterprise customers across 14 state of the art carrier neutral data centres spanning 8 cities. Our Hyperscale and colocation solutions allow our customers the freedom to plan effectively for the growth of their business, knowing that their data centre strategy is ready for the demands of tomorrow. We have over 25 years of experience in the industry, delivering on our vision of being the most trusted and customer centric data center operator in the market. We put environmental awareness at the heart of everything we do because we know it’s the right thing to do for our planet. That’s why we’re taking the ownership to reduce our environmental impact globally and make sustainability a key strategic driver. As part of our sustainability journey, alongside our sister company we are committed to achieving global net zero emissions for our own operations by 2030. https://www.coltdatacentres.net/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211102005298/en/
Contact information
AtlasEdge Corporate Communications:
Duncan White | duncan.white@atlasedge.com | +44 7970 974832
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom